Skip to main content
Fig. 5 | Clinical Epigenetics

Fig. 5

From: Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax

Fig. 5

PBX3 and BCL2 are two direct targets of miR-182. A and B An illustration of the potential binding sites of miR-182 in the 3'-UTR of PBX3 (A) and BCL2 (B). C HeLa cells were transfected with sicheck-2-PBX3-3'-UTR (WT) or sicheck-2-PBX3-3'-UTR (Mut) for 24 h, as well as with miR-182 mimics, or scramble (SCR) for another 24 h. Cell lysates were collected, and Firefly and Renilla luciferase activities were both measured. D HeLa cells were transfected with sicheck-2-BCL2-3'-UTR (WT) or sicheck-2- BCL2-3'-UTR (Mut) for 24 h, as well as miR-182 mimics, or SCR for another 24 h. Firefly and Renilla luciferase activities were both measured in the collected cell lysates. The Firefly/Renilla luciferase activities are shown. E and F The protein expression levels of PBX3 and BCL2 were measured in NALM-6 and Jurkat cells transduced with 182OE or Vec. G The protein expression levels of Pbx3 and Bcl2 were measured in BM GFP+ cells from murine 182WT and 182KO B-ALL model. ***P < 0.001

Back to article page